Tenofovir Alafenamide as Part of a Salvage Regimen in a Patient with Multi-Drug Resistant HIV and Tenofovir-DF-Associated Renal Tubulopathy | Zendy

James M Mikula | Zendy; Maura Manion | Zendy; Frank Maldarelli | Zendy; Lucila M Suarez | Zendy; Jaha F Norman-Wheeler | Zendy; Alex G Ober | Zendy; Robin Dewar | Zendy; Jeffrey B. Kopp | Zendy; H. Clifford Lane | Zendy; Alice K. Pau | Zendy

Open Access

Tenofovir Alafenamide as Part of a Salvage Regimen in a Patient with Multi-Drug Resistant HIV and Tenofovir-DF-Associated Renal Tubulopathy

Author(s) -

James M Mikula,

Maura Manion,

Frank Maldarelli,

Lucila M Suarez,

Jaha F Norman-Wheeler,

Alex G Ober,

Robin Dewar,

Jeffrey B. Kopp,

H. Clifford Lane,

Alice K. Pau

Publication year - 2015

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp3040

Subject(s) - tenofovir alafenamide , emtricitabine , medicine , cobicistat , renal function , regimen , fanconi syndrome , tenofovir , human immunodeficiency virus (hiv) , drug , kidney , gastroenterology , urology , virology , pharmacology , viral load , antiretroviral therapy

We describe a patient with two recent episodes of tenofovir disoproxil fumarate (TDF)-associated acute kidney injury and six-class drug-resistant HIV infection who achieved and maintained viral suppression without worsening kidney function on a regimen including tenofovir alafenamide (TAF) through 48 weeks of therapy. The safety and efficacy of TAF in patients with TDF-associated renal tubulopathy and multiple drug resistant HIV has not yet been described. TAF may represent a useful option to maximally suppress HIV in patients with these complications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research